Programmed death-ligand 1 (PD-L1) was reported to predict the response of immunotherapy; however, the association between PD-L1 expression and radiological/pathological features has yet to be elucidated.
A total of 292 patients with resected pathological stage I adenocarcinoma were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and the radiological/pathological invasiveness. Specifically, the radiological invasiveness and noninvasiveness were determined based on the consolidation/tumor (C/T) ratio, with a cut-off value of 0.25 by thin-section computed tomography.
Among 292 patients, 47 (16.1%) were positive for PD-L1 expression; the remaining 245 patients (83.9%) were negative for PD-L1 expression. Fisher’s exact test demonstrated that PD-L1 expression was significantly associated with a higher C/T ratio (P=0.029) and higher maximum standardized uptake value (SUVmax; P=0.004). The mean values of C/T ratio and SUVmax in patients with and without PD-L1 expression were 0.845±0.052 and 7.241±0.795, and 0.607±0.023 and 3.60±0.364, respectively (P
PD-L1 expression was significantly associated with radiological/pathological invasive adenocarcinomas. This study provides the first evidence of the radiological/pathological invasiveness in resected pathological stage I adenocarcinoma with PD-L1 expression.
Clinical trial identification
Legal entity responsible for the study
Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
All authors have declared no conflicts of interest.